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background:  The 2013 ACC/AHA guidelines for management of blood cholesterol (ACC/AHA) have substantially increased the number 
of asymptomatic adults who are eligible for primary preventive statin therapy. We sought to determine whether these new guidelines 
significantly improve the identification of individuals who develop incident cardiovascular disease (CVD) and/or have coronary artery 
calcium (CAC) compared to the 2004 NCEP ATPIII guideline (ATPIII).
Methods:  Statin eligibility was determined based on Framingham risk factors and LDL-thresholds for ATPIII, whereas the pooled cohort 
calculator was utilized for the ACC/AHA guideline. Participants were followed for a median of 8 years for incident major CVD (myocardial 
infarction, death from coronary heart disease, or ischemic stroke). CAC was measured by cardiac computed tomography. In the 
Framingham Heart Study participants in the Offspring and Third Generation cohorts free of known CVD, we determined risk for incident 
CVD based on statin eligibility using multivariate Cox proportional hazard models, and agreement of statin eligibility and presence of CAC 
for each guideline.
Results:  The study cohort consisted of 2452 statin-naïve participants (51.3 ± 8.6 yrs; 56% female) without prevalent CVD. In those eligible 
for statin versus not eligible, the hazard ratio for developing CVD was 3.28 (95%CI: 1.98-5.42) for the ATPIII versus 7.65 (95%CI: 4.10-
14.3) for the ACC/AHA guideline. (p=.0007) Of those with CAC>0 (n=1029), 23% were eligible for statin with the ATPIII guideline versus 
64% with the ACC/AHA guideline (p=.0001). More importantly, of those with CAC>= 300 (n=194), only 35% were eligible for statin with the 
ATPIII guideline versus 86% with the ACC/AHA guideline. (p<.0001) Conversely, of those with CAC=0 (n=1423), 7% were eligible for statin 
therapy with the ATPIII guideline versus 22% with the ACC/AHA guideline. (p<.0001)
conclusion:  The ACC/AHA guidelines provide significantly better allocation of statin therapy to those at increased risk for CVD and 
those with any or elevated levels of CAC as compared to the ATPIII guidelines, suggesting that the new guidelines will provide improved 
prevention of cardiovascular events.
